Literature DB >> 15502131

Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis.

Kathleen M Schmainda1, Scott D Rand, Allen M Joseph, Rebecca Lund, B Doug Ward, Arvind P Pathak, John L Ulmer, Michael A Badruddoja, Michael A Baddrudoja, Hendrikus G J Krouwer.   

Abstract

BACKGROUND AND
PURPOSE: No widespread clinical method provides specific information about the angiogenic characteristics of gliomas. We characterized blood volume and vascular morphologic parameters from combined gradient-echo (GE) and spin-echo (SE) MR imaging and assessed their relationship to tumor grade, a known correlate of glioma angiogenesis.
METHODS: Simultaneous GE and SE echo-planar imaging was performed with bolus gadolinium administration (0.20-0.25 mmol/kg) in 73 patients with glioma. To diminish possible T1 changes due to contrast agent extravasation, a preload (0.05-0.10 mmol/kg) was administered before the study, and a postprocessing correction algorithm was applied. Image maps of total (GE) and microvascular (SE) relative cerebral blood volume (rCBV) and the mean vessel diameter (mVD) calculated from the ratio of GE and SE relaxation rate changes (DeltaR2*/DeltaR2) were compared with tumor grade. A nonparametric K nearest-neighbor decision rule was applied to determine if the combined data could be used to distinguish low-grade (I-II) from high-grade (III-IV) tumors on a per-patient basis.
RESULTS: For whole tumors, significant correlations were found between GE rCBV and grade (P < .0001) and between mVD and grade (P = .0001) but not between SE rCBV and grade (P = .08). For areas of highest SE rCBV (microvascular hotspots), SE rCBV and tumor grade were significantly correlated (P = .0007). In terms of differentiation, 69% of low-grade tumors and 96% of high-grade tumors were correctly classified.
CONCLUSION: Combined GE and SE MR imaging provides information consistent with neoplastic angiogenesis, demonstrating its potential to aid in optimizing treatments, categorizing lesions, and influencing patient care. Copyright American Society of Neuroradiology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15502131      PMCID: PMC7976425     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  51 in total

1.  Optimization of fast acquisition methods for whole-brain relative cerebral blood volume (rCBV) mapping with susceptibility contrast agents.

Authors:  L Hou; Y Yang; V S Mattay; J A Frank; J H Duyn
Journal:  J Magn Reson Imaging       Date:  1999-02       Impact factor: 4.813

2.  Angiogenesis inhibitors revised and revived at AACR. American Association for Cancer Research.

Authors:  Kristine Novak
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

3.  MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis.

Authors:  A P Pathak; K M Schmainda; B D Ward; J R Linderman; K J Rebro; A S Greene
Journal:  Magn Reson Med       Date:  2001-10       Impact factor: 4.668

4.  Signal-to-noise analysis of cerebral blood volume maps from dynamic NMR imaging studies.

Authors:  J L Boxerman; B R Rosen; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1997 May-Jun       Impact factor: 4.813

5.  Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status.

Authors:  H J Bernsen; P F Rijken; J P Peters; J H Bakker; R H Boerman; P Wesseling; A J van der Kogel
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

6.  Microvessel density is a prognostic indicator for patients with astroglial brain tumors.

Authors:  S P Leon; R D Folkerth; P M Black
Journal:  Cancer       Date:  1996-01-15       Impact factor: 6.860

Review 7.  Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors.

Authors:  T Sugahara; Y Korogi; Y Shigematsu; L Liang; K Yoshizumi; M Kitajima; M Takahashi
Journal:  Top Magn Reson Imaging       Date:  1999-04

8.  Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy.

Authors:  M Fuss; F Wenz; M Essig; M Muenter; J Debus; T S Herman; M Wannenmacher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-10-01       Impact factor: 7.038

Review 9.  Vascular morphology and angiogenesis in glial tumors.

Authors:  K H Plate; H D Mennel
Journal:  Exp Toxicol Pathol       Date:  1995-05

10.  Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging.

Authors:  M Maeda; S Itoh; H Kimura; T Iwasaki; N Hayashi; K Yamamoto; Y Ishii; T Kubota
Journal:  Radiology       Date:  1993-10       Impact factor: 11.105

View more
  81 in total

Review 1.  Advances in the assessment of childhood brain tumors and treatment-related sequelae.

Authors:  Katherine E Warren
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

2.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

3.  Effects of perfusion on diffusion changes in human brain tumors.

Authors:  Alexander D Cohen; Peter S LaViolette; Melissa Prah; Jennifer Connelly; Mark G Malkin; Scott D Rand; Wade M Mueller; Kathleen M Schmainda
Journal:  J Magn Reson Imaging       Date:  2013-02-06       Impact factor: 4.813

4.  Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.

Authors:  Peter S LaViolette; Alex D Cohen; Melissa A Prah; Scott D Rand; Jennifer Connelly; Mark G Malkin; Wade M Mueller; Kathleen M Schmainda
Journal:  Neuro Oncol       Date:  2013-02-03       Impact factor: 12.300

5.  Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.

Authors:  Asim K Bag; Phillip C Cezayirli; Jake J Davenport; Santhosh Gaddikeri; Hassan M Fathallah-Shaykh; Alan Cantor; Xiaosi S Han; Louis B Nabors
Journal:  J Neurooncol       Date:  2014-08-07       Impact factor: 4.130

6.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Authors:  Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin
Journal:  Neuro Oncol       Date:  2014-01-15       Impact factor: 12.300

Review 7.  Imaging of central nervous system tumors in children: advances and limitations.

Authors:  Louis-Gilbert Vézina
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

8.  Advanced gastric cancer and perfusion imaging using a multidetector row computed tomography: correlation with prognostic determinants.

Authors:  Huan Zhang; Zilai Pan; Lianjun Du; Chao Yan; Bei Ding; Qi Song; Huawei Ling; Kemin Chen
Journal:  Korean J Radiol       Date:  2008 Mar-Apr       Impact factor: 3.500

9.  Impact of perfusion map analysis on early survival prediction accuracy in glioma patients.

Authors:  Benjamin Lemasson; Thomas L Chenevert; Theodore S Lawrence; Christina Tsien; Pia C Sundgren; Charles R Meyer; Larry Junck; Jennifer Boes; Stefanie Galbán; Timothy D Johnson; Alnawaz Rehemtulla; Brian D Ross; Craig J Galbán
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

10.  Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery.

Authors:  Koichi Mitsuya; Yoko Nakasu; Satoshi Horiguchi; Hideyuki Harada; Tetsuo Nishimura; Etsuro Bando; Hiroto Okawa; Yoshihiro Furukawa; Tatsuo Hirai; Masahiro Endo
Journal:  J Neurooncol       Date:  2010-01-08       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.